NASDAQ$RPTX
Repare Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Repare Therapeutics' fourth quarter and full year 2021 financial results were reported, with key milestones achieved in advancing the company's synthetic lethality-based pipeline.
Repare Therapeutics reported a net loss of $28.3 million for Q4 2021, with cash and cash equivalents and marketable securities totaling $341.9 million as of December 31, 2021. The company believes its current financial resources will fund operations through 2023. Key progress was made in the RP-3500 and RP-6306 programs.
- Initial Phase 1 RP-3500 monotherapy data from Phase 1/2 TRESR trial at AACR-NCI-EORTC provided clinical proof of concept and validated Repare’s SNIPRx platform.
- RP-3500 monotherapy appears safe and well tolerated, with compelling early efficacy signals across multiple genotypes and tumor types in heavily pretreated patients.
- Initiated a monotherapy Phase 2 TRESR trial of RP-3500 for the treatment of solid tumors with specific synthetic-lethal genomic alterations including those in the ATM gene in February 2022.
- In December 2021, the Company began dosing in a Phase 1 clinical trial of RP-6306 in combination with gemcitabine for the treatment of molecularly selected advanced solid tumors.
Headline financials
Revenue & EPS history
Repare Therapeutics · Revenue · Quarterly
$6.88M
Forward guidance
Repare Therapeutics anticipates several key milestones in 2022, including the Phase 2 expansion of the RP-3500 TRESR trial, initiation of the TRESR Phase 1 monotherapy pediatric module, and initial data from the Phase 1 RP-6306 monotherapy MYTHIC trial.
Tailwinds
- Initiation of a monotherapy Phase 2 TRESR trial of RP-3500 in February 2022.
- Initiation of recruitment in a Phase 1 pediatric module of TRESR trial of RP-3500 monotherapy with enrollment expected in Q1 2022.
- Comprehensive monotherapy Phase 1 (Module 1) clinical data from the TRESR trial of RP-3500 expected in Q2 2022.
- Determination of recommended Phase 2 dose of RP-3500 in combination with gemcitabine expected in the second half of 2022.
- Early clinical data readout for PARPi combination from Phase 1/2 TRESR trial and ATTACC trial of RP-3500 expected in Q3 2022.
Headwinds
- Potential delays in clinical trial site activation or enrollment rates.
- Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
- Changes in expected or existing competition.
- Changes in the regulatory environment.
- Uncertainties and timing of the regulatory approval process.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.7%
Q2 2023
Best reaction
-13.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -2.4% | +27.5% | +26.3% | |
| Q2 2025 | +0.0% | +3.3% | +11.2% | |
| Q1 2025 | +3.8% | +0.0% | +9.1% | |
| Q4 2024 | -1.7% | +0.9% | -9.4% | |
| Q3 2024 | -0.6% | -4.4% | -13.5% | |
| Q2 2024 | -4.8% | -8.3% | -11.9% | |
| Q1 2024 | +11.5% | +7.7% | +17.4% | |
| Q4 2023 | +4.4% | -0.6% | -29.9% | |
| Q3 2023 | -6.6% | — | — | |
| Q2 2023 | +19.7% | — | — | |
| Q1 2023 | +1.5% | — | — | |
| Q4 2022 | +2.0% | — | — | |
| Q3 2022 | +7.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.2% | — | — | |
| Q4 2021 | +0.4% | — | — | |
| Q3 2021 | +2.2% | — | — | |
| Q2 2021 | -0.2% | — | — | |
| Q1 2021 | +0.5% | — | — | |
| Q4 2020 | -13.5% | — | — | |
| Q3 2020 | -2.3% | — | — | |
| Q2 2020 | +2.6% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro